Astellas Pharma Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Astellas Pharma Inc. (ALPMY) develops, manufactures, markets, and distributes pharmaceutical products worldwide, with a focus on oncology, rare diseases, immunology, nephrology, urology, ophthalmology, and women's health; core brands include XTANDI and PADCEV for prostate and urothelial cancers, XOSPATA for acute myeloid leukemia, VYLOY (zolbetuximab) for gastric cancer, VEOZAH (fezolinetant) for menopause symptoms, IZERVAY (avacincaptad pegol) for geographic atrophy, EVRENZO for anemia in chronic kidney disease, BETANIS/Myrabetriq/BETMIGA for overactive bladder, and PROGRAF/Advagraf immunosuppressants for transplantation. Headquartered in Tokyo, Japan, and founded in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, the company operates in over 70 countries across Japan, the Americas, Europe, Middle East, Africa, and Asia-Oceania, employing more than 13,500 people and reporting fiscal 2024 revenue of ¥1,912.3 billion ($12.58 billion). Recent developments include a May 2025 licensing deal with Evopoint Biosciences for a CLDN18.2-targeting antibody-drug conjugate worth up to $1.34 billion, a 2024 TCR-T cell therapy collaboration with Poseida Therapeutics, a $50 million option agreement with AviadoBio in October 2024 for a frontotemporal dementia gene therapy, strategic investments in later-stage assets amid pipeline reprioritization, and ongoing partnerships such as with Vivtex Corporation for oral formulation technology and Roche Diabetes Care Japan for diabetes management solutions.
Astellas Targets ¥4.3 Trillion Profit Push As Xtandi Pressure Builds
MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Astellas Pharma Inc. (ALPMY) Q4 2026 Earnings Call Transcript
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare Transcript
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?
Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish
Astellas collaborates with Vir to develop its experimental prostate cancer drug
India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US
Astellas Pharma (OTCMKTS:ALPMY) Shares Pass Above Fifty Day Moving Average – What’s Next?
Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference
Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 294.1% in December
Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA)
Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study